Self-medication of regular headache: A community pharmacy-based survey

European Journal of Neurology

Volumn 19, Issue 8, 2012, Pages 1093-1099

  Mehuys, E ^a   Paemeleire, K ^b   Van Hees, T ^c   Christiaens, T ^a   Van Bortel, L M ^d   Van Tongelen, I ^a   De Bolle, L ^a   Remon, J P ^a   Boussery, K ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d GHENT UNIVERSITY   (Belgium)

Author keywords

Community pharmacy; Headache; Medication overuse; Self medication

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; BISOPROLOL; CAFFEINE; CODEINE; ERGOT ALKALOID; FLUNARIZINE; IBUPROFEN; LOSARTAN; NAPROXEN; NON PRESCRIPTION DRUG; OXETORONE; PARACETAMOL; PIZOTIFEN; PROGESTERONE; PROPRANOLOL; RIBOFLAVIN; TOPIRAMATE; TRIPTAN DERIVATIVE; VALPROIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CLUSTER HEADACHE; CONTROLLED STUDY; DISABILITY; DRUG ABUSE; DRUG INDUCED HEADACHE; EDUCATION; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MIGRAINE DISABILITY ASSESSMENT QUESTIONNAIRE; OBSERVATIONAL STUDY; PHYSICIAN; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; QUESTIONNAIRE; SELF MEDICATION; TENSION HEADACHE;

ADOLESCENT; ADULT; AGED; ANALGESICS; DATA COLLECTION; FEMALE; HEADACHE; HUMANS; MALE; MIDDLE AGED; NONPRESCRIPTION DRUGS; PHARMACIES; SELF MEDICATION;

EID: 84863882211     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2012.03681.x     Document Type: Article

References (37)

1. Evers S, Marziniak M. Clinical features, pathophysiology, and treatment of medication-overuse headache. Lancet Neurol 2010; 9: 391-401.
2. Stovner L, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 2007; 27: 193-210.
3. Wenzel RG, Schommer JC, Marks TG. Morbidity and medication preferences of individuals with headache presenting to a community pharmacy. Headache 2004; 44: 90-94.
4. Desamericq G, Revol A, Laforest L, et al. [Migraine or headache management: a pharmacy survey]. Therapie 2009; 64: 395-403.
5. Diener HC, Dowson A, Whicker S, Bacon T. Development and validation of a pharmacy migraine questionnaire to assess suitability for treatment with a triptan. J Headache Pain 2008; 9: 359-365.
6. Hoffmann W, Herzog B, Muhlig S, et al. Pharmaceutical care for migraine and headache patients: a community-based, randomized intervention. Ann Pharmacother 2008; 42: 1804-1813.
7. Silberstein SD, Olesen J, Bousser MG, et al. The International Classification of Headache Disorders, 2nd Edition (ICHD-II) - revision of criteria for 8.2 Medication-overuse headache. Cephalalgia 2005; 25: 460-465.
8. Lipton RB, Dodick D, Sadovsky R, et al. A self-administered screener for migraine in primary care: the ID Migraine validation study. Neurology 2003; 61: 375-382.
9. Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology 2001; 56(6 Suppl 1): S20-S28.
10. Stewart WF, Lipton RB, Kolodner K, Liberman J, Sawyer J. Reliability of the migraine disability assessment score in a population-based sample of headache sufferers. Cephalalgia 1999; 19: 107-114; discussion 74.
11. Stewart WF, Lipton RB, Whyte J, et al. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology 1999; 53: 988-994.
12. Kernick D, Stapley S, Hamilton W. GPs' classification of headache: is primary headache underdiagnosed? Br J Gen Pract 2008; 58: 102-104.
13. Lipton RB, Cady RK, Stewart WF, Wilks K, Hall C. Diagnostic lessons from the spectrum study. Neurology 2002; 58(9 Suppl 6): S27-S31.
14. Tepper SJ, Dahlof CG, Dowson A, et al. Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from the Landmark Study. Headache 2004; 44: 856-864.
15. Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache 2007; 47: 355-363.
16. Cevoli S, D'Amico D, Martelletti P, et al. Underdiagnosis and undertreatment of migraine in Italy: a survey of patients attending for the first time 10 headache centres. Cephalalgia 2009; 29: 1285-1293.
17. Kol CM, Dekker F, Neven AK, Assendelft WJ, Blom JW. Acceptance or rejection of prophylactic medicine in patients with migraine: a cross-sectional study. Br J Gen Pract 2008; 58: 98-101.
18. Lucas C, Chaffaut C, Artaz MA, Lanteri-Minet M. FRAMIG 2000: medical and therapeutic management of migraine in France. Cephalalgia 2005; 25: 267-279.
19. Steiner TJ, Martelletti P. Aids for management of common headache disorders in primary care. J Headache Pain 2007; 8(Suppl. 1): S2.
20. Silberstein SD, Winner PK, Chmiel JJ. Migraine preventive medication reduces resource utilization. Headache 2003; 43: 171-178.
21. D'Amico D, Solari A, Usai S, et al. Improvement in quality of life and activity limitations in migraine patients after prophylaxis. A prospective longitudinal multicentre study. Cephalalgia 2006; 26: 691-696.
22. Colman SS, Brod MI, Krishnamurthy A, Rowland CR, Jirgens KJ, Gomez-Mancilla B. Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan. Clin Ther 2001; 23: 127-145.
23. Dasbach EJ, Carides GW, Gerth WC, Santanello NC, Pigeon JG, Kramer Work and productivity loss in the rizatriptan multiple attack study. Cephalalgia 2000; 20: 830-834.
24. Lofland JH, Johnson NE, Batenhorst AS, Nash DB. Changes in resource use and outcomes for patients with migraine treated with sumatriptan: a managed care perspective. Arch Intern Med 1999; 159: 857-863.
25. Santanello NC, Polis AB, Hartmaier SL, Kramer MS, Block GA, Silberstein SD. Improvement in migraine-specific quality of life in a clinical trial of rizatriptan. Cephalalgia 1997; 17: 867-872; discussion 800.
26. Lainez MJ, Lopez A, Pascual AM. Effects on productivity and quality of life of rizatriptan for acute migraine: a workplace study. Headache 2005; 45: 883-890.
27. Lipton RB, Stewart WF, Simon D. Medical consultation for migraine: results from the American Migraine Study. Headache 1998; 38: 87-96.
28. Lipton RB, Stewart WF, Stone AM, Lainez MJ, Sawyer JP. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: a randomized trial. JAMA 2000; 284: 2599-2605.
29. Tfelt-Hansen P, Steiner TJ. Over-the-counter triptans for migraine: what are the implications? CNS Drugs 2007; 21: 877-883.
30. Lipton RB, Amatniek JC, Ferrari MD, Gross M. Migraine. Identifying and removing barriers to care. Neurology 1994; 44(6 Suppl 4): S63-S68.
31. Diener HC, Limmroth V. Medication-overuse headache: a worldwide problem. Lancet Neurol 2004; 3: 475-483.
32. Grande RB, Aaseth K, Benth JS, Lundqvist C, Russell MB. Reduction in medication-overuse headache after short information. The Akershus study of chronic headache. Eur J Neurol 2011; 18: 129-137.
33. Rossi P, Faroni JV, Nappi G. Short-term effectiveness of simple advice as a withdrawal strategy in simple and complicated medication overuse headache. Eur J Neurol 2011; 18: 396-401.
34. Gedikoglu U, Coskun O, Inan LE, Ucler S, Tunc T, Emre U. Validity and reliability of Turkish translation of Migraine Disability Assessment (MIDAS) questionnaire in patients with migraine. Cephalalgia 2005; 25: 452-456.
35. Cousins G, Hijazze S, Van de Laar FA, Fahey T. Diagnostic accuracy of the ID migraine: a systematic review and meta-analysis. Headache 2011; 51: 1140-1148.
36. D'Amico D, Mosconi P, Genco S, et al. The Migraine Disability Assessment (MIDAS) questionnaire: translation and reliability of the Italian version. Cephalalgia 2001; 21: 947-952.
37. Iigaya M, Sakai F, Kolodner KB, Lipton RB, Stewart WF. Reliability and validity of the Japanese Migraine Disability Assessment (MIDAS) Questionnaire. Headache 2003; 43: 343-352.